Skip to content

The Policy Vault

Methodology Why Contact

Coverage / Medica / Zelboraf (vemurafenib) / Non-small cell lung cancer

Zelboraf (vemurafenib) — Medica

Non-small cell lung cancer

Initial criteria

age ≥ 18 years
BRAF V600E mutation-positive disease

Approval duration

1 year

Provenance

View official policy PDF

Plan: Medica
Drug: Zelboraf (vemurafenib)
Indication: Non-small cell lung cancer
Last seen: 2025-10-06
Hash: 1be211198ee0…

Disclaimer: Educational only. Coverage varies by employer group and formulary. Always verify with the plan.

Consult

Curious about trends across plans?

I can walk you through how this policy compares and share data-backed patterns. Short call, straight answers.

Email to start a quick consult What I cover (overview)

No commitments—just a brief conversation to see if it’s helpful.

The Policy Vault

Structured prior authorization and step-therapy criteria for commercial health plans. Built by pharmacists for healthcare professionals.

Disclaimer: Educational use only. Coverage varies by employer group and formulary. Always verify with the plan.

Product

Coverage Directory
Why Policy Vault
Methodology

Company

Contact
Press
Support

© 2025 The Policy Vault. Data sourced from official health plan documents.